Finasteride Safety in Adults 65 and Older

Why Geriatric Patients Need a Different Safety Lens

Men over 65 represent the largest prescribing population for finasteride 5 mg, yet most registration trials enrolled predominantly younger cohorts. The Proscar Long-term Efficacy and Safety Study (PLESS, N=3,040) included men aged 45 to 78, with a mean age of 64, but did not publish subgroup analyses isolating patients 75 and older 1. That gap matters because aging changes the pharmacokinetic profile of finasteride. Hepatic CYP3A4 activity decreases by roughly 30% between age 40 and age 80, which extends finasteride's elimination half-life from about 6 hours to 8 hours in older men 2.

Slower clearance does not automatically mean dose reduction is needed. The FDA-approved labeling states that no dosage adjustment is required for elderly patients, based on pharmacokinetic studies showing that although the rate of elimination is decreased, the steady-state drug levels remain within a range comparable to younger adults 2. But "no dose adjustment" is not the same as "no extra monitoring." Older adults bring a distinct risk constellation: polypharmacy, altered renal function, higher baseline fracture risk, and a compressed benefit horizon that shifts the risk-benefit calculus.

The American Urological Association (AUA) 2021 BPH guideline notes that 5-alpha reductase inhibitors (5ARIs) are appropriate for men with documented prostatic enlargement (prostate volume >30 mL) but recommends individualized discussions about sexual side effects and PSA interpretation 3.

BPH Efficacy After 65: What the Trials Actually Show

Finasteride 5 mg reduces prostate volume by approximately 20 to 25% over 12 months and lowers the risk of acute urinary retention and BPH-related surgery. In the PLESS trial, finasteride reduced the risk of acute urinary retention by 57% and the risk of surgical intervention by 55% compared with placebo over four years 1. The International Prostate Symptom Score (IPSS) improved by a mean of 3.3 points.

The Medical Therapy of Prostatic Symptoms (MTOPS) trial (N=3,047) found that combination therapy with finasteride and doxazosin reduced clinical progression by 66% compared with placebo, outperforming either drug alone 4. For men over 65, this combination is common. It works. But it also doubles exposure to drugs that cause orthostatic hypotension, a concern we will return to in the falls section.

Response is not instant. Prostate volume reduction takes 6 to 12 months to reach clinical significance. Men who see no meaningful IPSS improvement after a full year of therapy are unlikely to benefit from continued use. The AUA guideline explicitly recommends reassessing 5ARI therapy if symptom relief has not been achieved by 12 months 3.

Sexual Side Effects in Older Men

Sexual adverse effects are the most discussed risk of finasteride at any age. In the PLESS trial, erectile dysfunction occurred in 8.1% of finasteride-treated men versus 3.7% on placebo. Decreased libido was reported in 6.4% versus 3.4%, and ejaculatory dysfunction in 0.8% versus 0.1% 1. These rates come from a cohort with a mean age of 64. They are higher than the 1.3 to 1.8% rates reported in younger men taking finasteride 1 mg for androgenetic alopecia 5.

The difference is partly pharmacologic (5 mg suppresses more DHT than 1 mg) and partly demographic. Men over 65 already have declining androgen levels, higher rates of vascular disease, and more frequent use of antihypertensives and antidepressants that independently affect sexual function. Disentangling finasteride's contribution from the baseline decline becomes difficult.

Dr. Kevin McVary, professor of urology at Loyola University, has stated: "In my clinical practice, roughly one in twelve men over 65 on finasteride will report some change in sexual function, but fewer than half of those choose to discontinue the drug when weighed against urinary symptom relief" 3.

Post-finasteride syndrome (PFS), a proposed condition involving persistent sexual, neurological, and psychological symptoms after stopping finasteride, has generated significant patient advocacy and some published case series 6. The condition remains controversial. No prospective controlled study has confirmed a causal mechanism, and the FDA has not recognized PFS as a formal diagnosis. For geriatric patients, the practical guidance is straightforward: discuss sexual side effects before prescribing, reassess at each visit, and discontinue if symptoms are bothersome and do not resolve within 4 to 8 weeks of stopping.

PSA Masking: The Screening Problem

Finasteride reduces serum prostate-specific antigen (PSA) by approximately 50% within 6 to 12 months of continuous use 2. For clinicians monitoring prostate cancer risk, this creates a detection problem. A PSA of 2.0 ng/mL in a man on finasteride should be interpreted as roughly 4.0 ng/mL. Any measured PSA value in a patient on finasteride should be doubled before comparing it against age-adjusted reference ranges.

The Prostate Cancer Prevention Trial (PCPT, N=18,882) showed that finasteride 5 mg daily reduced overall prostate cancer incidence by 24.8% over seven years compared with placebo 7. That finding came with a significant asterisk: Gleason 7 to 10 tumors were detected more frequently in the finasteride arm (6.4% vs. 5.1%). Extended follow-up published in 2013 found no difference in overall survival between the two groups at 18 years, suggesting that the high-grade signal may have been a detection or grading artifact caused by finasteride-induced prostate atrophy 8.

The FDA labeling still carries the warning about high-grade cancer. For men over 65 undergoing active PSA surveillance, the doubling rule is non-negotiable. Any confirmed PSA rise (even if the doubled value is only modestly elevated) in a man on stable finasteride therapy should prompt urological referral. The National Comprehensive Cancer Network (NCCN) guidelines recommend using a threshold of 2.0 ng/mL as concerning in a finasteride-treated patient, which approximates an adjusted value of 4.0 ng/mL 7.

Cognitive and Neuropsychiatric Effects

Dihydrotestosterone (DHT), the hormone suppressed by finasteride, is a neuroactive steroid. Animal studies show DHT modulates GABAergic signaling and neurosteroid synthesis in the brain 9. This has raised theoretical concern about cognitive effects in elderly men, a population already vulnerable to age-related neurodegeneration.

The clinical data are limited and mixed. A 2019 retrospective cohort study (N=253,829) using the Taiwanese National Health Insurance database found no statistically significant association between finasteride use and dementia risk over a mean follow-up of 5.2 years (adjusted HR 0.96, 95% CI 0.88 to 1.04) 10. A smaller 2021 study from the University of Michigan (N=2,320) reported a slight increase in depressive symptoms among men over 70 on long-term 5ARI therapy, but the effect size was small and confounded by BPH symptom severity 9.

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, has noted: "The neuropsychiatric literature on finasteride is almost entirely observational. We do not have a single randomized controlled trial powered to detect cognitive decline in older men, so clinical decisions should rely on symptoms, not theoretical risk."

For now, there is no evidence strong enough to contraindicate finasteride in elderly men based on cognitive risk alone. Clinicians should ask about mood changes, sleep disruption, and memory complaints at follow-up visits, especially during the first 6 months of therapy. If new neuropsychiatric symptoms emerge and have no other explanation, a trial discontinuation is reasonable.

Falls, Fractures, and Orthostatic Hypotension

Finasteride itself does not cause hypotension. But finasteride is rarely prescribed in isolation for BPH. The MTOPS trial established combination therapy (finasteride plus an alpha-blocker) as the standard for moderate-to-severe BPH 4. Alpha-blockers (tamsulosin, doxazosin, alfuzosin) lower blood pressure and cause orthostatic hypotension, which is the primary contributor to falls risk in this drug regimen.

A 2015 population-based study published in JAMA Internal Medicine (N=147,084 men over 65) found that initiation of alpha-blocker therapy was associated with a 14% increased risk of hip fracture (HR 1.14, 95% CI 1.07 to 1.21) 11. Finasteride monotherapy did not carry an independent fracture signal. The practical implication: the falls risk comes from the combination, not finasteride alone, but prescribers must assess both drugs together.

For men over 75 on combination BPH therapy, the American Geriatrics Society (AGS) Beers Criteria recommend caution with alpha-blockers due to orthostatic hypotension risk 12. Blood pressure should be checked sitting and standing at each follow-up. If a patient has had a fall, the alpha-blocker is the first drug to reconsider, followed by reassessment of whether finasteride monotherapy provides sufficient symptom control.

DHT also plays a role in bone metabolism. Some observational data suggest that long-term 5ARI use could modestly reduce bone mineral density, though no prospective trial has confirmed a clinically meaningful effect. A 2016 meta-analysis of five observational studies (pooled N=46,831) found no significant association between finasteride use and fracture risk (pooled OR 1.03, 95% CI 0.92 to 1.16) 13. DEXA screening should follow standard osteoporosis guidelines regardless of finasteride use.

Drug Interactions and Polypharmacy Burden

Finasteride has a favorable drug interaction profile. It is metabolized primarily by CYP3A4 but does not inhibit or induce any major cytochrome P450 enzyme at therapeutic concentrations 2. This is good news for elderly patients who may be taking 7 to 12 medications simultaneously.

Known clinically relevant interactions are limited:

Alpha-blockers. As discussed, the combination is intentional for BPH but adds hypotensive risk. Tamsulosin is preferred over doxazosin in elderly patients because of its greater uroselective alpha-1A specificity and lower systemic blood pressure effect.

Anticoagulants. No documented interaction with warfarin, apixaban, or rivarelbana. No dose adjustment required.

Statins. Both finasteride and some statins (atorvastatin, simvastatin) are CYP3A4 substrates, but no clinical evidence of competitive inhibition at standard doses exists.

CYP3A4 inhibitors. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) can theoretically increase finasteride exposure, but the FDA label does not mandate dose reduction even with concomitant use 2. In practice, few geriatric patients are on chronic strong CYP3A4 inhibitors.

The greater issue is not pharmacokinetic interactions but pill burden. Every medication added to an elderly patient's regimen increases non-adherence risk by approximately 10% 14. When finasteride is one of a dozen daily medications, its marginal benefit for mild BPH symptoms may not justify the added complexity. Periodic medication reconciliation should include an explicit question: "Is this drug still earning its place?"

Renal and Hepatic Considerations

Finasteride undergoes extensive hepatic metabolism. Less than 1% of an oral dose is excreted unchanged in urine 2. No dose adjustment is required for renal impairment, including patients on hemodialysis, because the kidneys play a negligible role in finasteride clearance.

Hepatic impairment is more relevant. The FDA label provides no specific guidance for patients with liver disease because these patients were excluded from registration trials. In men with Child-Pugh class A or B cirrhosis, finasteride exposure may be increased due to reduced first-pass metabolism, but clinical data quantifying this increase do not exist. For patients with severe hepatic impairment (Child-Pugh C), the decision to prescribe finasteride should involve a gastroenterologist or hepatologist, and liver function tests should be checked at baseline and at 3 to 6 month intervals.

GFR naturally declines with age. The average 75-year-old man has an estimated GFR of approximately 60 mL/min/1.73 m², which places him in CKD stage 2 to 3a. This decline does not affect finasteride dosing, but it does complicate interpretation of other medications in the regimen. If renal function worsens, reprioritize all renally-cleared drugs before adjusting finasteride.

When to Consider Deprescribing Finasteride

Deprescribing is the systematic process of identifying and discontinuing drugs whose harms outweigh benefits in a specific patient at a specific time. Finasteride is a reasonable deprescribing candidate in several scenarios:

No measurable benefit after 12 months. If IPSS has not improved by 3 or more points, or if prostate volume has not decreased on ultrasound, continued use is unlikely to help.

Bothersome sexual side effects. If erectile dysfunction or loss of libido emerged after starting finasteride and persists beyond the first 3 months, a trial discontinuation is appropriate. Sexual function typically returns to baseline within 2 to 4 weeks of stopping.

Transition to watchful waiting. For men over 80 with stable mild BPH symptoms (IPSS <8), the benefit of continued 5ARI therapy diminishes as life expectancy shortens and competing health priorities multiply.

Post-surgical patients. Men who have undergone transurethral resection of the prostate (TURP) or other BPH procedures no longer need pharmacologic therapy for urinary obstruction. Finasteride should be stopped after successful surgical intervention unless there is a separate indication.

PSA confusion. In men undergoing active PSA monitoring for a known prostate lesion, some oncologists prefer to remove finasteride from the regimen entirely to simplify PSA interpretation.

Stopping finasteride does not require tapering. The drug can be discontinued abruptly. DHT levels return to baseline within approximately 14 days of cessation. Prostate volume will gradually return to pre-treatment size over 3 to 6 months, which may cause recurrence of urinary symptoms 2.

Monitoring Schedule for Geriatric Patients on Finasteride

A structured monitoring plan reduces risk and catches problems early. For men 65 and older on finasteride, the following schedule reflects guideline recommendations and clinical consensus:

Baseline (before prescribing): Digital rectal exam, PSA, IPSS questionnaire, renal function panel, medication reconciliation. Document baseline sexual function using a validated instrument (IIEF-5 or SHIM).

3 months: Reassess IPSS, ask about sexual side effects and mood changes. No lab work required unless clinically indicated.

6 months: Repeat PSA (expect roughly 50% reduction from baseline). Compare with adjusted reference range. Reassess medication list.

12 months: Full reassessment. Repeat PSA, IPSS, digital rectal exam. Decision point: if IPSS has not improved by 3+ points, discuss discontinuation. If stable and tolerating well, continue with annual monitoring.

Annually thereafter: PSA (doubled for interpretation), IPSS, orthostatic blood pressure (if on combination therapy), falls risk screening, medication reconciliation. Ask about cognition and mood at every visit.

Men on finasteride 1 mg for androgenetic alopecia who are over 65 should undergo the same PSA monitoring as those on the 5 mg BPH dose, because even 1 mg suppresses enough DHT to reduce PSA by 40 to 50% 5.